Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume 102, Issue 12A, Pages 14L-18LPublisher
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2008.09.069
Keywords
-
Categories
Funding
- Abbott Laboratories
- Merck
- Pfizer Inc.
- Schering Plough
- Sonosite
Ask authors/readers for more resources
Patients with type 2 diabetes mellitus or metabolic syndrome typically exhibit atherogenic mixed dyslipidemia characterized by low levels of high-density lipoprotein cholesterol, elevated triglycerides, and an increase in small, dense low-density lipoprotein particles. Treatment guidelines recognize lifestyle intervention as a first step in the management of dyslipidemia in these patients. The aim of this article is to review evidence to support this approach. To achieve all recommended lipid goals in clinical practice, lifestyle intervention is likely to be adjunctive to pharmacotherapy. (c) 2008 Elsevier Inc. All rights reserved. (Am J Cardiol 2008;102[suppl]:14L-18L)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available